Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3784212 | 0.93 | ALDH1A1 (0.56) | ADRB2ADRB1ADRB3MGLLLPAR1 | |
| SCHEMBL1892709 | 0.93 | ALDH1A1 (0.56) | ADRB2ADRB1ADRB3MGLLLPAR1 | |
| SCHEMBL15061844 | 0.93 | MGLL (0.61) | ADRB2ADRB1ADRB3MGLLLPAR1 | |
| SCHEMBL27665720 | 0.88 | ALDH1A1 (0.69) | MGLLLPAR1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31744536 | 0.88 | ADRB2 (0.56) | ADRB2ADRB1ADRB3MGLLLPAR1 | |
| SCHEMBL4255720 | 0.86 | ALDH1A1 (0.54) | MGLLLPAR1MAPK1ALDH1A1LMNA | |
| SCHEMBL15061850 | 0.86 | ADRB2 (0.53) | ADRB2ADRB1ADRB3LPAR1TDP1 | |
| SCHEMBL15048706 | 0.86 | ADRB2 (0.53) | ADRB2ADRB1ADRB3LPAR1TDP1 | |
| SCHEMBL15061853 | 0.86 | TLR2 (0.48) | ADRB2ADRB1ADRB3MGLLLPAR1 | |
| SCHEMBL15048720 | 0.86 | TLR2 (0.48) | ADRB2ADRB1ADRB3MGLLLPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221954-A1 | METHODS TO TREAT, PREVENT, OR REDUCE HYPERAMMONEMIA | RUBIN DARREN ALEXANDER (US) | 2025-07-10 | — | — | US | claimed |
| WO-2024261477-A1 | COMBINATION OF TLR4 ANTAGONIST, ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE | YAQRIT LIMITED (GB) | 2024-12-26 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024105168-A1 | NOVEL COMBINATIONS USEFUL FOR THE TREATMENTS OF ALS | INFLECTIS BIOSCIENCE (FR) | 2024-05-23 | — | — | WO | claimed |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-17 | — | — | US | claimed |
| CN-114929209-A | Treatment of amyotrophic lateral sclerosis | 艾米利克斯制药公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114929211-A | Compositions of bile acid and phenylbutyric acid compounds | 艾米利克斯制药公司 | 2022-08-19 | — | — | CN | claimed |
| US-20220249010-A1 | METHODS OF ASSESSING HEPATIC ENCEPHALOPATHY | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2022-08-11 | — | — | US | claimed |
| EP-3965659-A1 | METHODS OF ASSESSING AND TREATING HEPATIC ENCEPHALOPATHY | Ocera Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | claimed |
| CN-113995743-A | Therapeutic monitoring of phenylacetic acid prodrugs | 伊梅尔迪卡制药公司 | 2022-02-01 | — | — | CN | claimed |
| CN-113966194-A | Methods of assessing and treating hepatic encephalopathy | 欧塞拉治疗有限公司 | 2022-01-21 | — | — | CN | claimed |
| WO-2020070760-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 1,2,3-PROPANETRIYL TRIS(4-PHENYLBUTANOATE) | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2020-04-09 | — | — | WO | claimed |
| WO-2026104570-A1 | LIPOSOMAL SUSPENSION AND SYSTEM AND METHOD OF PERITONEAL ADMINISTRATION OF LIPOSOMAL SUSPENSION | GENFIT (FR) | 2026-05-21 | — | — | WO | disclosed |
| US-20260076927-A1 | PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF | ACER THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260048134-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | ENDOREL BIOSCIENCES LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12551461-B2 | Compositions of triglycerides and uses thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2010025303-A9 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010025303-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2010-01-14 | — | — | US | disclosed |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551461-B2 | Compositions of triglycerides and uses thereof | DAGLB, PNLIP, LIPC | ADRB2 209/4885ADRB1 142/4885ADRB3 65/4885 |
| US-20260048134-A1 | PEPTIDE-BASED DELIVERY AGENT AND METHOD OF MAKING AND USING THE SAME | FABP1, LAMP1, SLC7A1 | ADRB2 3394/4885ADRB1 3351/4885ADRB3 3818/4885 |
| US-20260076927-A1 | PALATABLE COMPOSITIONS INCLUDING SODIUM PHENYLBUTYRATE AND USES THEREOF | BCKDK, MLYCD, HADHB | ADRB2 3783/4885ADRB1 3436/4885ADRB3 3502/4885 |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | OAT, SLC1A5, GLS | ADRB2 3848/4885ADRB1 3421/4885ADRB3 2980/4885 |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | OAT, ABAT, BCKDK | ADRB2 2725/4885ADRB1 1772/4885ADRB3 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.